MOLECULAR DIAGNOSTICS MARKET ANALYSIS

Molecular Diagnostics Market, By Product Type (Reagents & Kits, and Instruments), By Application (Oncology, Genetic Testing, Microbiology, STDs, Blood Screening, Virology, Tissue Typing, Prenatal Diagnosis, and Others), By End-User (Hospitals and Diagnostic Laboratories, Academic and Research Institutes, Pharmaceutical and Biotechnology Companies, Contract Research Organizations, and Point-of-Care Settings), By Geography (North America, Latin America, Europe, Asia Pacific, Middle East & Africa)

On August 5, 2024, Baylor Genetics and Baylor College of Medicine launched the Medical Genetics Multi-Omics Laboratory (MGML). Their first test, Whole Transcriptomic RNA Sequencing (WT RNAseq), identifies disease-causing genes in blood and skin cells that may be missed by other sequencing methods.
In July 2024, MedGenome has acquired a stake in Odisha-based, GenX Diagnostics, to enhance its presence in East India. The partnership aims to improve healthcare services by combining diagnostic and genomic expertise. GenX Diagnostics, founded in 2017, operates seven diagnostic centers and 60 collection centers across Odisha, India.
In July 2024, Illumina acquired Fluent BioSciences, a company specializing in single-cell analysis technology, with the deal closing on June 9 and funded with cash on hand. The acquisition, including Fluent’s PIPseq V technology, will enhance Illumina’s single-cell analysis capabilities and integrate into its product portfolio. Illumina plans to build comprehensive solutions from Fluent's technology while continuing to support existing single-cell partnerships
In July 2024, Roche completed its acquisition of LumiraDx’s Point of Care technology, following all necessary regulatory approvals. Roche will now integrate LumiraDx’s multi-assay point of care platform and related operations into its global organization.